MitoQ before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether taking the supplement MitoQ before standard surgery can help treat triple-negative breast cancer. You would take MitoQ for a short time between diagnosis and surgery to see if it slows tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with triple-negative breast cancer that is confirmed by a biopsy.
- Your cancer has not been treated yet with any systemic therapy (like chemotherapy or targeted drugs).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You are willing to use effective birth control if you could become pregnant.
- You have a tumor sample (in a block or at least 20 unstained slides) that can be tested in the lab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if the treatment shrinks the tumor enough to make surgery more effective.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.